In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Twist Bioscience Corp.

www.twistbioscience.com

Latest From Twist Bioscience Corp.

Twist Bioscience: DNA Research Tools Put Fresh Spin On Drug Discovery

Speed and efficiency are fundamental to the success of today’s biopharmaceutical enterprise, but the hunt is still on for transformative technologies to boost pipeline productivity and growth. One answer may lie in the arrival of replicable, synthetic versions of DNA.

Innovation Research and Development Strategies

Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'

Pivotal and Biomatics launch new VC funds totaling $300m and $200m, respectively; Spero raises a $51.7m Series C round; BeyondSpring is March's only US IPO, so far; Aurinia and TG Therapeutics capitalize on positive data with secondary offerings; and Galena hires a "strategic review" advisor.

Commercial Financing

Synthetic Biology And The Computerization Of Drug Development

Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.

BioPharmaceutical Innovation

Device/Diagnostics Quarterly Deal Statistics, Q1 2016

Device companies raised 50% more in Q1 2016 than the previous quarter, reaching $1.8 billion and led by debt offerings; diagnostic imaging acquisitions, such as Toshiba Medical Systems, were abundant. Diagnostics financings double in Q1, mostly from venture funding, including strong showing from liquid biopsy companies.

Medical Device Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Synthesis Technologies, Production Processes
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Twist Bioscience Corp.
  • Senior Management
  • Emily Leproust, PhD, CEO
    Jim Thornburn, CFO
    Bill Peck, PhD, CTO
    Bill Banyai, PhD, COO
    Martin Kunz, SVP, Ops.
  • Contact Info
  • Twist Bioscience Corp.
    Phone: (408) 410-0105
    455 Mission Bay Blvd. S.
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register